Latest Content

Explore 2026 psychiatry practice M&A: surging demand, selective buyers, valuation premiums for scale, and the workforce/parity rules reshaping deals.

FDA approves Takeda’s Orzeyful, first orexin agonist, improving wakefulness and reducing cataplexy in adults with narcolepsy type 1 in pivotal trials.

Explore suicide prevention in psychiatry—risk assessment, treatment challenges, and emerging research. Submit your case or CME for August 2026.

New case suggests muscarinic therapy xanomeline/trospium calms treatment‑resistant bipolar I mania with psychosis, hinting at nondopamine options.

Two psychiatrists use poetry and therapy to unpack clinician trauma, residency transformation, and how discomfort becomes a tool for patient connection.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.

Fitbit and Google Health app data feed Amae clinicians real-time sleep, physical activity, and heart rate variability signals to spot relapse early in severe mental illness.

Clancy trial spotlights postpartum psychosis: how to recognize warning signs, emergency treatment options, and why stigma and DSM gaps hinder care.

Explore Alzheimer’s breakthroughs: lecanemab, donanemab, FDA blood tests, 2024 criteria, and new options to ease agitation and improve care.

Study of 470 BIPOC adults in residential care finds the Unified Treatment Model sustains reductions in eating disorder, depressive, and anxiety symptoms.

New Alzheimer trial news highlights safer anti-amyloid PMN310, cannabinoids easing agitation, tau gene therapy progress, FDA Fast Track psychosis drug, and TBI inflammation targets.

Experts discuss the impact of the placebo effect on psychiatric treatment outcomes.

Check out the pipeline updates from July!